The World Health Organization (WHO) has released new reports which state that a lack of innovation in new antibiotic development is undermining efforts to combat drug-resistant infections.
List view / Grid view
Filter the results
A new report has said the majority of the active ingredients used in pharmaceuticals have never been evaluated for environmental risks.
The US FDA has granted approval for the marketing authorisation of Talicia, intended to treat adults with H. pylori infection.
The UK government will invest £3.5 million to help develop new antibitoic treatments for gonorrhoea and make them available to low- and middle-income countries.
The fight against antibiotic resistance could be improved with the discovery of a concept for fabricating nanomeshes as a drug delivery system.
Why has the pharma industry and its talents lost interest in developing new antibiotics?
The worldwide trade of the cephalosporin class of antibiotics will increase to $14.1 billion by the end of 2025.
The CMA alleges that a pharmaceutical company agreed to buy equal quantities of a pill from two drug suppliers, breaking competition law.
The NHS is set to launch a new payment method for antibiotic development to incentivise pharmaceutical companies.
According to Rutgers researchers, physicians are scaling back on prescribing antibiotics for long-term acne treatment in favour of a combination of therapies.
The pharmaceutical industry needs to match words with action on researching new antibiotics to address the threat posed by drug-resistant superbugs...
This article covers the analytical criteria that apply to Bacterial Endotoxin Testing (BET) using Limulus Amebocyte Lysate (LAL) or recombinant Horseshoe crab Factor C (rFC) for the bioactivity determination of endotoxin in aqueous solutions, such as pharmaceuticals and medical device extracts. It explains the importance of these criteria for accurate…
The next five years will see game-changing improvements made in upstream, downstream and continuous bioprocessing, predicts one industry specialist...
Monoclonal antibodies (mAbs) are widely manufactured by many biopharmaceutical companies to treat a myriad of diseases ranging from Alzheimer’s disease, Parkinson’s disease, ulcerative colitis, and many types of cancers...